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Abstract
Background: Little is known in our country about regional 
differences in the treatment of acute coronary disease.
Objective: To analyze the behavior regarding the use of 
demonstrably effective regional therapies in acute coronary 
disease.
Methods: A total of 71 hospitals were randomly selected, 
respecting the proportionality of the country in relation to 
geographic location, among other criteria. In the overall 
population was regionally analyzed the use of aspirin, 
clopidogrel, ACE inhibitors / AT1 blocker, beta-blockers and 
statins, separately and grouped by individual score ranging 
from 0 (no drug used) to 100 (all drugs used). In myocardial 
infarction with ST elevation (STEMI) regional differences were 
analyzed regarding the use of therapeutic recanalization 
(fibrinolytics and primary angioplasty). 
Results: In the overall population, within the first 24 
hours of hospitalization, the mean score in the North-
Northeast (70.5 ± 22.1) was lower (p <0.05) than in the 
Southeast (77.7 ± 29.5), Midwest (82 ± 22.1) and South 
(82.4 ± 21) regions. At hospital discharge, the score of the 
North-Northeast region (61.4 ± 32.9) was lower (p <0.05) 
than in the Southeast (69.2 ± 31.6), Midwest (65.3 ± 33.6) 
and South (73.7 ± 28.1) regions; additionally, the score of 
the Midwest was lower (p <0.05) than the South region. In 
STEMI, the use of recanalization therapies was highest in 
the Southeast (75.4%, p = 0.001 compared to the rest of 
the country), and lowest in the North-Northeast (52.5%, p 
<0.001 compared to the rest of the country). 
Conclusion: The use of demonstrably effective therapies in 
the treatment of acute coronary disease is much to be desired 
in the country, with important regional differences.
Introduction
According to the latest data released by the World Health 
Organization (WHO) (2008), Coronary Artery Disease (CAD) 
remains the main cause of worldwide mortality, accounting 
for approximately 16% of all deaths in developed countries, 
and approximately 12% in developing or underdeveloped 
ones1. The vast majority, in absolute numbers, occurs in 
the latter group of countries (82% in 2004, last information 
available)2. In Brazil, CAD was responsible for 96,386 
deaths according to 2009 data provided by the Datasus 
(approximately 9% of all deaths in the year), the vast majority 
related to acute myocardial infarction3. 
As expected, Acute Coronary Syndromes (ACS - unstable 
angina and acute myocardial infarction with or without 
ST-segment elevation) are responsible for high costs in 
healthcare, and the implementation of public and private 
policies to minimize the effects of these numbers depends 
on comprehensive studies in order that properly reflect 
their diagnostic and therapeutic management.
Brazil has participated in several national and international 
multicenter studies/registries4-6 on unstable myocardial 
ischemic syndromes, which has allowed surveys on the 
approaches used in the participating centers; however, 
these centers do not necessarily reflect the country’s reality 
as a whole, as they are chosen taking into account specific 
features such as complexity, presence of certain procedures, 
previous experience in research, location etc. Frequently, 
data are obtained from participating centers in international 
multicenter studies, thus following the criteria for patient 
and center selection in accordance with the requirements 
of the study itself.
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Thus, hospital registries with a stratified and random 
selection of centers, in order to obtain more reliable and 
comprehensive data about what occurs in Brazil are mandatory. 
The BRACE study aimed to fill this gap and evaluates regional 
differences regarding the use of demonstrably effective 
therapies to treat patients with ACS (“therapeutic variables 
of performance”). 
Methods
Main Objective 
The main objective of the present study is to analyze the 
behavior of specialized services representing different regions 
of the country, regarding the use of demonstrably effective 
therapies in the treatment of patients with acute coronary 
disease (use of acetyl salicylic acid, clopidogrel, beta blockers, 
statins and recanalization therapy). 
Sample design 
Of a sample of 123,774 healthcare establishments 
registered at the Ministry of Health, 576 public and private 
hospitals were identified that met the criteria of having a 
Cardiology Unit and Intensive Care Unit (ICU). Considering the 
study setting, and taking into account the minimum number 
of patients to be included, a sample of 70 to 80 centers was 
calculated as the ideal number of hospitals, based on the 
methodology that will be outlined below. 
1. The selected hospitals are representative of all 
the hospitals with ICU and Cardiology Unit in 
Brazil, stratified according to: geographic region, 
administrative characteristics (public or private), and 
whether it was a university hospital or not.
2. We adopted the methodology of “cluster sampling”. 
Cluster sampling consists in exclusive and collectively 
exhaustive subpopulations, i.e., every element of the 
population is classified in one and only one of the 
clusters. Based on that, we selected a random sample 
of clusters (hospitals). 
3. For the selection of clusters, the “proportional 
stratified sampling” methodology was applied – with 
the geographic areas being considered as strata. As 
the clusters, the strata are exclusive and collectively 
exhaustive subpopulations, in a way that the strata 
are the most homogeneous in their formation and the 
most heterogeneous when compared to each other. 
Using to this cluster sample design, the proportionality 
was taken into account regarding the geographic areas 
the sponsor entity (public and private) as to whether 
or not it was a university hospital. That is, the same 
proportions found in the setting were maintained 
in the sample, for each of the variables of interest. 
Within each stratum, a random sample of hospitals 
was obtained. 
4. Each hospital was contacted through its randomly 
selected Clinical Director and/or director of Cardiology 
Unit and invited to participate. Where they were 
unwilling or unable to participate, the hospital was 
replaced by another, also at random, with exactly 
the same characteristics as the one initially selected. 
5. For substitutions, in addition to the variables 
characterizing the strata (region, the administrative 
characteristics, university and teaching hospital status) 
we also considered the complexity of the hospital, 
when there was an equivalent center.
Of the initially contacted hospitals and that agreed to 
participate in the study, 33 were substituted, resulting in a final 
sample of 71 hospitals that supplied data to the study. As the 
characteristics of the replaced centers (region, administrative 
characteristics, university and teaching hospital status) were 
taken into account, randomization was maintained throughout 
research development. 
Sample size
The initial estimation of sample size was based on the need 
for reading/analysis of patient data segmented by variables 
such as geographic region, gender, age, ethnicity, habits of 
the patient and several others.
Based on this need, the final sample size was defined as 
1,067 patients, considered sufficient for readings with such 
segmentations.
This sample size allows reading of the total data with 
a maximum margin of error of three points, considering a 
confidence level of 95%. 
To determine the sample size, the following were specified: 
1) (E) – Expected accuracy level for results, i.e., the margin 
of error (established as three percentage points upwards or 
downwards); 
2) Level of confidence of the sample (set at 95%), which 
means: if the study was conducted 100 times, under the same 
conditions, in 95 of them the created interval should contain 
the true value of the parameter; 
3) (p) – Estimate of the population proportion generating 
the highest variability (as the population proportion is 
unknown, we chose to define it as p = 0.5, thus adopting the 
highest variability, and ensuring the widest interval; 
4) (z) – Z value (normal distribution) associated to the 
established level of confidence (z=1.96).
Considering the values adopted for each of the above items, 
sample size was determined through the formula: 
N = p(1-p)(z/E) 2
N = 0.5(1-0.5)(1.96/0.03)2
N = 1067
With this minimum sample one ensures that, for any 
proportion found, the results can be read with a maximum 
error of three percentage points, with a confidence level of 95%.
In centers where there was no Research Ethics Committee 
(60% of the total – Brazilian reality!), The Ethics Committee 
in Research of HCFMUSP reviewed and approved the survey 
and are therefore responsible for resolving any questions or 
problems encountered at these sites.
In order to evaluate the consistency of information 
obtained at BRACE, especially regarding the sampling 
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distribution, questions such as incidence of myocardial 
infarction in the family of the respondent and incidence 
of death related to myocardial infarction were included 
in questionnaires of parallel national surveys carried out 
by Datafolha. 
When the patient arrived at the hospital, the staff was 
directed to contact a “0800” number and the patient 
was registered into the system. The training of teams and 
monitoring tutoring was in charge of a specialized firm hired 
specifically for this purpose (Eurotrials). 
The entire methodology was developed by specialized 
Datafolha staff, which was also responsible for its 
implementation, collection/storage of data in a specific 
database, and also by the survey results presented here. 
The General Coordination of the study was supervised by 
the Study Group on Coronary Artery Disease, Emergency and 
Intensive Care (Geceti) of the Brazilian Society of Cardiology 
together with the Acute Coronary Disease Unit, Instituto do 
Coração (InCor) / HCFMUSP, with the support the Brazilian 
Ministry of Health. The study was registered at the specialized 
American website “RegistriesLive.org” (www.registrieslive.org). 
Statistical Analysis 
When comparing categorical variables, the chi-square e 
Fisher exact tests were applied; the analysis of continuous 
variables was performed using the Mann-Whitney and 
Student t test, as indicated. The different regions of Brazil 
were compared at first, and each one of them was compared 
with the rest of the country in sequential analysis. Taking 
into account the individual use of therapeutic variables of 
performance, we developed a score for each patient, which 
could vary from 0 (no therapeutics used) to 100 (using the 
five treatments).
Subsequently, the scores of each region were compared 
using the ANOVA test for non-repeated measures with Tukey’s 
post-test. Because they had very similar results, the North and 
Northeast regions were grouped together for statistical analysis. 
P-value <0.05 (two-tailed) was considered significant. SPSS 
software release 16.0 was used for all analyzes.
Results
The characteristics of the hospitals are described in 
Table 1. The distribution of hospitals, as expected by the 
method employed, shows a majority of them located in the 
Southeast, followed by the Northeast, South, Midwest and 
North regions. Together, these institutions included a total 
of 1,150 patients in the registry. Approximately one quarter 
of hospitals belong to the public sector (18 hospitals, seven 
of federal, eight state and three municipal administration), 
and 10% were university ones. 
The demographic characteristics of the study population 
are shown in Table 2. Of the total patients, 733 (63.7%) 
were males and 417 (36.3%), females; the mean age was 
63.1 years and 797 patients (70.1%) were Caucasians. 
Upon arrival at the hospital, a history of hypertension 
was present in more than two-thirds of patients, diabetes 
mellitus in one-fourth and hypercholesterolemia in more 
than one-third of the population. More than half of the 
patients reported tobacco use (current or previous), and 
approximately one quarter had a history of myocardial 
infarction.
Data related to therapeutics used were obtained, in 
the registry, in two stages: prescription within 24 hours 
of hospitalization, and prescription at hospital discharge. 
Tables 3, 4 and 5 show the use of these therapies in the 
total population, and taking into account the different 
regions analyzed.
Acetylsalicylic acid (ASA) was administered to 89% of 
patients within 24 hours of hospitalization and 86% at 
discharge, being more often prescribed during this period 
in the South (91.2%, p = 0.007 in relation to the rest of 
the country) and less often in the Midwest (80.2%, p = 
0.002). Regarding the use of beta blockers, 66.8% of the 
population received the drugs within the first 24 hours, 
and 69.8% at discharge; this analysis (at discharge) showed 
significant differences between regions, with the highest 
percentage of prescriptions of beta blockers in the South 
Region (79.3%, p = 0.001) and the lowest in the Midwest 
(64.3%, p = 0.028).
The use of angiotensin-converting enzyme inhibitors 
(ACEI) and angiotensin-receptor blockers (ARB), it was 
observed that 67.2% of patients received this class of 
drugs within the 24 hours and 70.6% at hospital discharge, 
whereas patients in the Midwest received this medication 
less often at discharge (64.3%, p = 0.012). As for statins, 
they were prescribed to 78.7% of the population within 24 
hours of hospitalization, also heterogeneously in different 
regions, being more commonly prescribed in the South 
(86.6% of the population, p <0.001) and less commonly 
Table 1 – Participating hospitals per region
South
Prev./ Incl.
Southeast
Prev./  Incl.
Midwest
Prev. / Incl.
North
Prev. / Incl.
Northeast
Prev./  Incl.
Total
n (%)
Total (%) 17.5 / 18.3 46.25 /46.5 12.5 / 9.9 5.0 / 5.6 18.75 / 19.7 71  (100)
Type (%)
Public
Private
2.5 / 7.1
15 /11.3
11.25 / 7.1
35 / 39.4
2.5 / 4.2
10 / 5.6
1.25 / 1.4
3.75 / 4.2
5 / 5.6
13.75 / 14.1
22.5 / 25.4
77.5 / 74.6
University % 2.5 / 4.2 3.75 / 2.8 1.25 / 1.4 0 / 0 1.25 / 1.4 8.75 / 9.9
Prev. - previewed; Incl. - included.
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prescribed in the Midwest (72.6%, p = 0.006). At hospital 
discharge, 82.7% of the population were prescribed statins, 
with an unequal distribution in different regions of Brazil, 
with the highest percentages in the South (92%%, p <0.001) 
and lowest in the Midwest (76.6 %, p = 0.003). 
Clopidogrel was administered within 24 hours of hospital 
admission in 59.7% of cases, with an unequal distribution 
throughout the country (p <0.001). Populations in the 
Southeast (67.4%, p <0.001) and South (65.1%, p = 0.042) 
were more likely to receive clopidogrel, while only 42.2% of 
the population of North-Northeast Region received this drug 
on the first day of hospitalization (OR 0.410, p <0.001). At 
hospital discharge, this antiplatelet agent was prescribed to 
50.1% of the population, with its prescription being more 
frequent in the South (57.4%, p = 0.009) and less frequent 
in the North-Northeast regions (35.1%, p <0.001). 
Tables 6 and 7 show the mean score of the use of 
therapeutic variables of performance in the several regions 
Table 2 – Demographic characteristics of the studied population
Regions South Southeast Midwest Northeast North Total
Total patients included 269 399 259 173 50 1150
Male sex (n; %) 184; 68.4 265; 66.4 159; 61.4 91; 52.6 34; 68 733; 63.7
Mean age (years) 63.3 63.1 61 65.64 64.92 63.6
Ethnicity (n; %)
Caucasian
Black
Brazilian mulatto
Asian
221; 82.1
11; 4.1
32; 11.9
2; 0.7
298; 74.7
26; 6.5
73; 18.3
1; 0.2
145; 56
40; 15.4
73; 28.2
1; 0.4
99; 57.2
10; 5.8
56; 32.4
0; 0
34; 68
3; 6
12; 24
0; 0
797; 69.3
90; 7.8
246; 21.4
4; 0.3
History of SAH (N; %) 175; 65 283; 70.9 180; 69.5 120; 69.3 41; 82 799; 69.5
History of DM (N; %) 64; 23.8 101; 25.3 62; 23.9 49; 28.3 12; 24 288; 25
History of HCL (N; %) 128; 47.6 138; 34.6 66; 25.5 68; 39.3 19; 38 419; 36.4
Family history of CAD (N; %) 169; 62.8 166; 41.6 106; 40.9 99; 57.2 12; 24 552; 48
Smoking (N; %)
Current
Previous
180; 66.9
95; 35.3
85; 31.6
221; 55.4
128; 32.1
93; 23.3
157; 60.6
68; 26.2
89; 34.4
78; 45.1
37; 21.4
41; 23.7
30; 60
11; 22
19; 38
666; 57.9
339; 29.5
327; 28.4
Previous AMI  (n;%) 67; 24.9 82; 20.5 60; 23.2 35; 20.2 13; 26 257; 22.3
Previous CA (n; %) 129; 47.9 195; 48.8 76; 29.3 62; 35.8 26; 52 488; 42.4
Previous HF (n; %) 28; 10.4 22; 5.5 26; 10 5; 2.9 2; 4 83; 7.2
Previous PCI (n; %) 59; 21.9 48; 12 24; 9.3 19; 11 7; 14 157; 13.6
Previous CABG (n; %) 39; 14.5 37; 9.3 17; 6.6 16; 9.2 6; 12 115; 10
Previous CRF (n;%) 15; 5.6 11; 2.7 3; 1.1 5; 2.9 3; 6 37; 3.2
Previous CVA (n; %) 21; 7.8 20; 5.0 14; 5.4 11; 6.4 2; 4 68; 5.9
Previous PAD (n; %) 25; 9.3 21; 5.3 4; 1.5 3; 1.7 3; 6 56; 4.9
Previous COPD (n; %) 22; 8.2 29; 7.3 13; 5 11; 6.4 6; 12 81; 7
SAH - systemic arterial hypertension; DM - diabetes mellitus; HCL - hypercholesterolemia; CAD - coronary artery disease; AMI - acute myocardial infarction; 
CA - chest angina; HF-heat failure; PCI - percutaneous coronary intervention; CABG - coronary artery bypass graft; CRF - chronic renal failure; CVA - cerebrovascular 
accident; PAD -peripheral artery disease; COPD - chronic obstructive pulmonary disease.
Table 3 – Overall use of therapeutic variables of performance in the total study population
1st 24 hours Hospital discharge
ASA (n;%) 1024 (89%) 930 (86%)
Clopidogrel (n;%) 687 (59,7%) 542 (50,1%)
Beta-blocker (n;%) 768 (66,8%) 755 (69,8%)
ACEI/ARB (n;%) 773 (67,2%) 763 (70,6%)
Statin (n;%) 905 (78,7%) 894 (82,7%)
ASA - acetyl salicylic acid; ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker.
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analyzed. As it can be observed, similarly to the individual 
analyses of the previously described therapies, the North-
Northeast region had significantly lower performance 
when compared to the other regions of the country, both 
regarding the use of drugs within the first 24 hours of 
admission, and drug prescription at hospital discharge. 
Additionally, at the discharge, the Midwest Region had a 
lower performance, when compared to the South Region.
When assessing the overall rates of reperfusion therapy 
use in patients with AMI with ST elevation (fibrinolysis 
or primary angioplasty), the disparity persists among the 
country regions (p = 0.001), with reperfusion therapies 
most often used in the Southeast (75.4% - OR 1.858, 95% 
CI 1.274 to 2.709, p = 0.001) and less frequently in the 
North-Northeast region (52.5% - OR 0.475, 95% CI 0.316 
to 0.714, p <0.001) (Fig. 1). 
When patients with contraindications to the use of 
reperfusion therapy, mainly to fibrinolytic agents (recent 
surgery or trauma, bleeding or coagulopathy, persistent 
hypertension, concomitant disease, time from onset of 
symptoms greater than 12 hours, current treatment with 
anticoagulant) are excluded from this sample, the scenario 
persists with statistically significant differences, albeit less 
exuberant, with the therapy being less used in the North-
Northeast (82.9%, p = 0.003), and more used in the South 
region (96.3%, p = 0.044).  
Discussion
The BRACE registry is, to the best of our knowledge, the first 
national registry in its field to apply the present methodology 
to assess the reality of the country as a whole, in regard 
to hospital treatment of acute coronary disease. This has 
important implications on the obtained results and appraisal of 
epidemiological data for purposes of public policies, as it can be 
used to direct efforts in areas where the greatest need is evident.
In general, the use of the therapies reviewed here is 
lower than that reported in current registries, even those that 
specifically included patients from developing countries. For 
example, the ACCESS6 registry, which included more than 
12,000 patients from Latin America, Africa and the Middle 
East, reports percentage (at hospital discharge) of 90%, 76%, 
89% and 76%, respectively, for ASA, beta-blockers, statins and 
clopidogrel, rates that are well above those found in our country. 
However, these differences, at least in part, must be related to 
the methodology employed, as in the ACCESS registry, center 
selection (as in similar registries) was not exactly representative 
of the country as a whole, as recognized by the authors in their 
publication.
Regarding the main objective of this publication, it was 
shown that there are significant regional differences in the use 
of demonstrably effective therapies in the treatment of ACS, 
which is somewhat expected in a large country with continental 
dimensions and recognized heterogeneities, such as Brazil. 
Table 4 – Use of therapeutic variables of performance within the first 24 hours of hospitalization
South
n (%)
Southeast
n (%)
Midwest
n (%)
Northeast
n (%)
North
n (%) p
ASA 248 (92,2) 347 (87) 232 (89,6) 154 (89%) 43 (86%) 0,282
Beta-blockers 190 (70,6) 252 (63,2) 180 (69,5) 111 (64,2) 35 (70) 0,215
ACEI / ARB 171 (63,6) 277 (69,4) 179 (69,1) 117 (67,6) 29 (58) 0,301
Statin 233 (86,6)* 312 (78,2) 188 (72,6)** 130 (75,1) 42 (84) 0,001
Clopidogrel 175 (65,1)# 269 (67,4)## 149 (57,5) 68 (39,3)$ 26 (52)$ <0,001
ASA - acetyl salicylic acid; ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker. * p < 0.001 (OR=2.01) in relation to the rest of the 
country; ** p = 0.006 (OR = 0.64) in relation to the rest of the country; # p = 0.042 (OR=1.34) in relation to the rest of the country; ## p < 0.001 (OR = 1.65) in relation 
to the rest of the country; $ p < 0.001 (OR = 0.41) when comparing North/Northeast region and the rest of the country.
Table 5 – Prescription of therapeutic variables of performance at hospital discharge.
South
n (%)
Southeast
n (%)
Midwest
n (%)
Northeast
n (%)
North
n (%) p
ASA 229 (91.2)* 328 (87.9) 202 (80.2)** 134 (85.9) 37 (75.5) 0.001
Beta-blockers 199 (79.3)# 262 (70.2) 162 (64.3)## 104 (66.7) 28 (57.1) 0.001
ACEI / ARB 188 (74.9) 270 (72.4) 162 (64.3)& 107 (68.6) 36 (73.5) 0.086
Statin 231 (92)$ 304 (81.5) 193 (76.6)$$ 126 (80.8) 40 (81.6) <0.001
Clopidogrel 144 (57.4)£ 200 (53.6) 126 (50) 53 (34)££ 19 (38.8)££ <0.001
ASA - acetyl salicylic acid; ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker. * p = 0.007 (OR=1.916) in relation to the rest of the 
country; ** p = 0.002 (OR = 0.56) in relation to the rest of the country; # p < 0.001 (OR = 1.886) in relation to the rest of the country; ## p = 0.028 (OR = 0.716) in 
relation to the rest of the country; &p = 0.012 (OR = 0.683) in relation to the rest of the country; $ p < 0.001 (OR = 2.909) in relation to the rest of the country; $$ p = 
0.003 (OR = 0.597) in relation to the rest of the country; £ p = 0.009 (OR = 1.461) in relation to the rest of the country; ££ p < 0.001 (OR = 0.468) when comparing 
North/Northeast region and the rest of the country.
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Table 6 – Mean scores of use of therapeutic variables of performance within the first 24 hours of hospitalization
Regions Mean score D.P. 95% L.C.I. 95% U.C.S.
Midwest 82.01* 22.11 79.30 84.71
North/Northeast 70.49 27.56 66.86 74.13
Southeast 77.69 * 29.45 74.80 80.59
South 82.38 * 20.95 79.86 84.89
S.D. - standard-deviation; L.C.I. - lower confidence interval; U.C.I. - upper confidence interval. * p < 0.05 vs. North/Northeast; other comparisons p = NS.
Table 7 – Mean scores of prescription of the performance variables at hospital discharge
Regions Mean S.D. 95% L.C.I. 95% U.C.I.
Midwest 65.25 *† 33.55 61.15 69.36
North/Northeast 61.35 32.88 57.01 65.68
Southeast 69.22 * 31.63 66.11 72.34
South 73.68 * 28.13 70.30 77.06
S.D. - standard-deviation; L.C.I. - lower confidence interval; U.C.I. - upper confidence interval. * p < 0.05 vs. North/Northeast, † p < 0.05 vs. South.
Figure 1 – Overall reperfusion therapy in AMI with ST elevation. S - South; SE - Southeast; MW - Midwest; N/NE - North/Northeast. p - 0.001 in the comparison between 
SE and the rest of the country.  p < 0.001 in the comparison between N/NE and the rest of the country.
While patients from the South and Southeast regions more 
often receive these therapies, patients in the North-Northeast 
regions are less likely to be treated as recommended by 
national7,8 and international9-11 guidelines. These results may 
explain, at least partially, epidemiological mortality data 
previously published in our country12, which has shown 
that mortality due to ischemic heart disease in the five 
regions of Brazil has decreased in the South and Southeast 
regions, remained stable in the Midwest and increased in the 
Northeast. Or, more comprehensively, if we take into account 
observations of increase in mortality due to CAD in the less 
developed regions and decrease in more developed regions 
in the world13,14, one can hypothesize that the impact of 
improvement in the use of demonstrably effective therapies 
in the treatment of unstable myocardial ischemic syndromes 
would be greater in less developed countries, when compared 
to developed ones.  
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Specifically regarding the use of myocardial reperfusion 
therapy (fibrinolysis or primary PCI) in acute myocardial 
infarction with ST-segment elevation, the same pattern 
repeats itself. 
Both in the overall population, as well as when patients 
with justifications for not using these therapies (most due 
to time between symptom onset and hospital arrival > 
12 hours) are excluded, clearly the patients in the North-
Northeast region are also those who less often receive these 
treatments. Two important corollaries can be proposed 
from these findings: patients in some regions of the country 
tend to take longer to get to specialized medical services 
for the treatment of ACS (this fact can be explained by the 
delay in recognizing the urgency and the difficult access 
to healthcare services) and when they do get treated, 
they do not receive, at appropriate proportions, available 
demonstrably effective therapies. 
Thus, it is clear that only the urgent implementation of 
educational measures aimed at the population about acute 
coronary disease symptoms and the need for specialized 
emergency medical service in the presence of these symptoms, 
as well as easier access to health care associated with the 
proper training of professionals involved in the process and 
organization of networks that increase system effectiveness 
can improve the described scenario. Within this context, 
proposals such as the one by the Ministry of Health, to provide 
second-generation fibrinolytic and antiplatelet treatment for 
the whole country and to implement 40 new Coronary Units 
in several regions of Brazil, among other measures (Minister 
Alexandre Padilha, SBC Congress 09/2011 , InCor 12.13.2011 
and Diario Oficial da Uniao, 31/12/2011), are very welcome, 
and can contribute significantly to improve the treatment of 
acute coronary disease in our country.
Study limitations
As any record, it also has some limitations. First, it should 
be noted that patients treated at isolated Emergency Units 
were not included in it. Due to a logistic problem, the current 
research was restricted to hospitals qualified by the Ministry 
of Health to care for cardiac cases, and which had an ICU. 
Second, as in almost all similar registries, there was no making 
sure that the data of all patients that came to the hospital with 
the characteristics required by the study were included in it. 
Finally, it must be recalled that the vast majority of centers had 
no previous experience in research; however, it is possible 
that they have improved their performance precisely because 
they participated in a study with the scope of present one15, 
which somehow could overestimate the country performance 
as a whole. Because of these limitations, the consistency of 
the obtained information was carefully checked by inserting 
questions on the subject in national surveys carried out by 
Datafolha. The answers to these questions allowed an estimation 
of the incidence of individuals that suffered a myocardial 
infarction, incidence of individuals that suffered myocardial 
infarctions that sought hospital care and incidence of infarction-
related death, as well as its regional distribution. As mentioned 
before, the data thus observed were consistent with those 
obtained in the present registry, indirectly validating it.
Conclusions
The present study clearly demonstrates the important 
regional differences that occur in Brazil regarding the adoption 
of appropriate medical procedures in patients with acute 
coronary disease. Given the high prevalence of this disease in 
our population, and the preventable adverse consequences 
associated with this heterogeneity, impact measures to improve 
the overall and regional performance of centers where these 
therapeutic approaches are employed in Brazil should be 
prioritized by our government and by the Scientific Societies 
involved in these processes. 
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Appendix 1 - Participating centers, 
city-state (main investigator)
Santa Casa de Maceió – AL (Sandra Batista dos Santos); 
Hospital Adventista de Manaus – AM (Ricardo Chaves); Real 
Sociedade Espanhola de Beneficência - Hospital Espanhol, 
Salvador – BA (Fábio Vilas Boas); Hospital Salvador, Salvador – 
BA (Cláudio Marcelo Bittencourt das Virgens); Hospital Geral de 
Vitória da Conquista – BA (Luis Cláudio Menezes de Carvalho); 
Hospital Antonio Prudente, Fortaleza – CE (Ricardo Lessa de 
Castro Júnior); Hospital Brasília – DF (Tullio Xavier Leirias); 
Instituto do Coração – DF ( Luis Gustavo Ferreira); ProntoNorte, 
Brasília – DF (Rosana Costa Oliveira); MS Hospital dos Servidores 
do Estado, Rio de Janeiro – RJ (Luiz Maurino Abreu); Hospital 
Metropolitano, Serra – ES (Hermes Carloni Araújo); Hospital 
Memorial São Francisco, João Pessoa – PB (Francisco Ítalo 
Kumamoto); Hospital Dr. João Felício, Juiz de Fora – MG 
(Antonio Muniz); Hospital Ipiranga, São Paulo – SP (Fernando 
Lara Roquette); Santa Casa de Belo Horizonte – MG (Mário Lúcio 
Perez); Casa de Caridade de Carangola – MG (Rodrigo Di Mingo); 
Hospital Santa Rita, Contagem – MG (Álvaro Camisão de Souza); 
Hospital São Lucas, Governador Valadares – MG (Alexandre 
Becalli Rabelo); Hospital Vaz Monteiro, Lavras – MG (Marcos 
Cherem); Hospital São José do Avaí, Itaperuna – RJ (Antonio 
Carlos Botelho da Silva); Santa Casa de Misericórdia de Poços de 
Caldas – MG (José Tasca); Hospital Santa Genoveva, Uberlândia – 
MG (Eduardo Tiveron Veludo); Hospital de Cardiologia Procordis, 
Niterói – RJ (José Geraldo Amino); Hospital Regional de Mato 
Grosso do Sul, Campo Grande – MS (Emmanuela Nunes da 
Costa); Hospital Universitário Maria Aparecida Pedrossian – 
UFMS, Campo Grande – MS (Delcio Gonçalves Silva Junior); 
Hospital Santa Rita, Dourados – MS (Fernando Fonseca Gouvea); 
AMECOR, Cuiabá – MT (Ubirajara Lupoli Barbosa); FUSVAG, 
Várzea Grande – MT (Agnaldo Solon Arruda Ajambuja); Unidade 
de Emergência da UNIMED, Manaus – AM (Rovanda Guimarães 
Sena Marques); Hospital Regional Dr. Janduhy Carneiro, Patos – 
PB (Klauber Marques de França); Hospital Unimed, João Pessoa 
– PB  (Eugênia Di Giuseppe Deininger); Hospital Agamenon 
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